BRAF and neoplasm: Demographic parameters, tumour characteristics, whether primary or recurrent before new therapy, therapy characteristics such as length and time till the second course of adjuvant treatment, and AE, whether any or drug related, showed no significance comparing PD‐1 and BRAF + MEK‐treated patients (Table S1).